VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AXGNAxoGen, Inc.
$44.93$2.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAXGNBalance Sheet

AxoGen, Inc. (AXGN) Balance Sheet

30Y historyFree accessUpdated daily

The company significantly improved its financial flexibility by reducing total debt to $20.6M in 2026Q1, down from $69.3M in 2023Q4.

AXGN Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Jun'01Jun'00Jun'99Jun'98Jun'97Jun'96
Total Current Assets184.71M120.42M99.22M88M98.08M127.05M145.25M135.02M150.95M55.74M44.04M35.05M14.41M25.66M18.3M10.88M10.09M16.77M454.26K996.23K1.35M1.59M2.57M2M2.11M3.79M5.24M4.7M6.2M6.9M5.4M
Cash & Short-Term Investments82.65M35.55M33.48M31.02M48.79M84.09M103.97M96.51M116.61M36.51M30.01M25.91M8.22M20.07M13.91M8.19M7.08M15.77M332.85K832.92K1.28M1.31M2.24M483.84K671.59K1.43M100.17K01M700K800K
Cash Only82.65M35.55M27.55M31.02M15.28M32.76M48.77M35.72M24.29M36.51M30.01M25.91M8.22M20.07M13.91M8.19M7.08M15.77M332.85K832.92K1.28M1.31M2.24M483.84K671.59K1.43M100.17K01M700K800K
Short-Term Investments005.93M033.51M51.33M55.2M60.79M92.31M0000000000000000000000
Accounts Receivable28.31M26.17M24.11M25.15M22.19M18.16M17.62M16.94M15.32M11.06M8.05M4.78M2.87M1.89M1.05M797.65K407.35K31.52K32.59K100.43K0214.91K0203.87K318.9K547.84K1.58M2M2.7M2.3M2.1M
Days Sales Outstanding43.4242.4146.9757.7258.4352.0457.2657.9666.6266.8471.563.8862.3463.1449.8360.041.63K0.46163.58365-176.93-10.2816.9912.5539.4659.3576.468.2558.51
Inventory46.07M42.37M33.18M23.02M18.91M16.69M12.53M13.86M11.98M7.32M5.46M3.93M3.21M3.4M3.15M1.76M1.01M0000001.09M1.01M1.53M2.25M2.1M1.9M2.6M2M
Days Inventory Outstanding254.29267.33267.01226.21231.75265.71211.9291.62338.42286.77308.09296.16340.76508.41586.25264.82-------72.6370.7853.0795.7610582.56137.54104.29
Other Current Assets27.67M16.33M8.45M6M6.25M6.25M6.84M6M6M853.38K511.8K424.93K109.37K296.72K187.26K133.5K1.08M00000192.63K634.22K003.28M600K600K1M500K
Total Non-Current Assets104.78M101.27M104.51M108.82M97.31M80.97M56.13M19.62M9.22M3.13M2.32M2.49M1.99M2.03M1.93M1.61M56.31K35.38K69.99K103.76K166.59K232.61K233.21K688.66K2.04M2.56M3.24M4.1M4.4M4.9M6.9M
Property, Plant & Equipment97.32M94.52M98.93M104.29M93.66M78.12M54.08M18.11M8.04M2.2M1.49M970.87K619.03K381.69K108.53K247.82K3.65K5.57K5.93K0000477.06K1.75M2.26M3.04M3.9M4.1M4.6M5.1M
Fixed Asset Turnover2.49x2.38x1.89x1.52x1.48x1.63x2.08x5.89x10.44x27.50x27.51x28.15x27.17x28.68x70.87x19.57x25.02x4473.22x12.26x----15.17x3.91x7.04x4.80x3.15x3.15x2.67x2.57x
Goodwill000000000000000169.99K000000000000000
Intangible Assets7.27M6.75M5.58M4.53M3.65M2.86M2.05M1.51M1.18M936.99K828.98K678.08K577.17K570.4K573.73K899.48K52.66K29.81K43.77K42.92K65.19K90.65K50.69K211.59K285.86K297.07K199.35K200K300K400K600K
Long-Term Investments0000000000000000000000000000000
Other Non-Current Assets192K0000000000845.73K793.5K1.07M1.25M295.28K0-474K20.28K-4.62M101.4K141.96K182.51K000000-100K1.2M
Total Assets289.49M221.69M203.73M196.83M195.39M208.02M201.38M154.64M160.17M58.87M46.36M37.55M16.4M27.68M20.23M12.5M10.14M16.81M524.24K1.1M1.51M1.82M2.8M2.69M4.15M6.35M8.47M8.8M10.6M11.8M12.3M
Asset Turnover1.02x1.02x0.92x0.81x0.71x0.61x0.56x0.69x0.52x1.03x0.89x0.73x1.03x0.40x0.38x0.39x0.01x1.48x0.14x0.09x0.08x0.24x0.38x2.69x1.65x2.51x1.72x1.40x1.22x1.04x1.07x
Asset Growth %77.85%8.82%3.51%0.74%-6.07%3.3%30.22%-3.45%172.06%26.99%23.48%128.93%-40.76%36.84%61.91%23.18%-39.65%3106.23%-52.34%-27.38%-17%-34.9%4.18%-35.17%-34.64%-25.07%-3.7%-16.98%-10.17%-4.06%-3.15%
Total Current Liabilities26.01M23.56M30.61M30.43M23.75M24.29M22.83M20.88M13.04M13.72M11.08M3.71M2.45M2.1M1.48M2.02M114.35K5.75M211.06K201.17K217.87K160.86K521.05K2.78M3.17M2.68M3.72M2.5M2M2.8M1.2M
Accounts Payable008.01M11.77M8.96M5.92M4.6M8.26M4.52M3.24M3.61M2.11M1.16M1.18M1.22M1.59M62.3K84.66K26.16K13.41K14.48K10.49K4.94K19.8K587.65K628.36K1.18M1.7M1.5M800K800K
Days Payables Outstanding34.92-64.44115.7109.8994.2877.75173.82127.58126.92203.97158.55123.09176.74227.1238.43-------1.3241.1521.8350.18565.1842.3241.71
Short-Term Debt2.12M2.37M0000863K1.74M28K735.02K4.05M0000434.73K0000002.52K12.56K1.15M938.8K860.1K0000
Deferred Revenue (Current)000000014K18K31.67K33.28K14.12K14.12K14.12K0-1.59M000000240.29K502.38K780.51K1.04M00000
Other Current Liabilities23.9M21.18M18.58M009.67M12.73M7.62M2M7.94M-804.69K000009.27M48K130K130K130K98.35K273.29K2.61M650.07K75K229.44K800K500K2M400K
Current Ratio7.10x5.11x3.24x2.89x4.13x5.23x6.36x6.47x11.57x4.06x3.97x9.45x5.89x12.23x12.36x5.39x88.21x2.92x2.15x4.95x6.19x9.90x4.93x0.72x0.67x1.41x1.41x1.88x3.10x2.46x4.50x
Quick Ratio5.33x3.31x2.16x2.14x3.33x4.54x5.81x5.80x10.65x3.53x3.48x8.39x4.58x10.61x10.23x4.52x79.39x2.92x2.15x4.95x6.19x9.90x4.93x0.33x0.35x0.84x0.80x1.04x2.15x1.54x2.83x
Cash Conversion Cycle262.79-249.54168.24180.3223.47191.42175.75277.47226.69175.62201.49280.01394.81408.9886.43-------81.646.6243.7985.1279.3593.78163.47121.08
Total Non-Current Liabilities18.67M69.28M69.21M70.73M70.64M71.18M55.4M1.61M147K19.97M20.36M25.64M25.2M25.45M21.58M4.4M62.3K84.66K26.16K13.41K14.48K10.49K7.47K62.44K10.77K125.17K31.18K200K200K200K200K
Long-Term Debt18.53M16.87M47.5M46.6M45.71M44.82M32.03M1.59M35K19.91M20.27M24.7M25.09M25.36M21.58M4.4M000000062.44K10.77K125.17K31.18K0000
Capital Lease Obligations35.46M019.22M21.14M20.41M20.8M20.87M1.59M00000000000000000000000
Deferred Tax Liabilities000000000-164K-92.22K-25.55M-25.09M-570.82K000-48K000000000200K200K200K200K
Other Non-Current Liabilities140K52.41M2.49M2.99M4.52M5.56M2.5M-1.59M70K000000062.3K00000000000000
Total Liabilities44.68M92.84M99.82M101.16M94.39M95.47M78.23M22.49M13.19M33.69M31.44M29.35M27.65M27.55M23.06M6.42M114.35K5.75M211.06K201.17K217.87K160.86K521.05K2.84M3.18M2.81M3.75M2.7M2.2M3M1.4M
Total Debt20.64M19.24M68.69M69.29M67.43M67.45M54.63M4.93M63K24.64M24.31M25.55M25.09M25.36M21.58M4.84M8.4M000002.52K295K1.17M1.06M891.29K0000
Net Debt-62.01M-16.31M41.13M38.27M52.14M34.7M5.86M-30.8M-24.23M-11.87M-5.7M-362.08K16.87M5.29M7.67M-3.35M1.32M-15.77M-332.85K-832.92K-1.28M-1.31M-2.24M-188.84K493.59K-361.24K791.12K0-1M-700K-800K
Debt / Equity0.08x0.15x0.66x0.72x0.67x0.60x0.44x0.04x0.00x0.98x1.63x3.12x-185.63x-0.80x0.84x-----0.00x-1.21x0.30x0.19x----
Debt / EBITDA-8.16x55.94x15.10x-------------------0.03x--------
Net Debt / EBITDA24.50x-47.40x9.04x---------------0.99x-----25.51x------2.50x-0.64x-1.60x
Interest Coverage-0.05x-1.04x-0.21x-6.66x-45.39x-18.90x-21.57x-727.38x-17.54x-3.24x-1.30x-2.24x-1.24x-1.91x-3.27x-2.98x-2.10x-------42.74x-19.01x-0.88x----0.18x-
Total Equity244.81M128.85M103.91M95.67M101M112.55M123.15M132.15M146.98M25.18M14.92M8.2M-11.25M136.63K-2.83M6.07M10.03M11.06M313.19K898.82K1.3M1.66M2.28M-153.77K966.8K3.54M4.72M6.1M8.4M8.8M10.9M
Equity Growth %195.21%24%8.62%-5.28%-10.26%-8.61%-6.81%-10.09%483.68%68.77%82.06%172.88%-8330.57%104.83%-146.6%-39.46%-9.33%3431.81%-65.16%-30.69%-22.07%-27.09%1584.11%-115.9%-72.69%-24.99%-22.63%-27.38%-4.55%-19.27%-2.68%
Book Value per Share4.752.802.352.232.402.733.083.373.960.760.490.31-0.630.01-0.261.642.332.570.070.220.310.400.55-0.040.240.901.211.542.102.282.87
Total Shareholders' Equity244.81M128.85M103.91M95.67M101M112.55M123.15M132.15M146.98M25.18M14.92M8.2M-11.25M136.63K-2.83M6.07M10.03M11.06M313.19K898.82K1.3M1.66M2.28M-153.77K966.8K3.54M4.72M6.1M8.4M8.8M10.9M
Common Stock532K472K441K431K424K417K406K396K389K343.5K330.09K299.85K194.89K173.4K111.23K110.62K43.05K42.9K42.9K41.76K41.49K41.49K40.3K39.79K39.66K39.41K39.05K0000
Retained Earnings-326.55M-306.96M-291.26M-281.3M-259.58M-230.63M-203.65M-179.86M-150.73M-128.33M-117.88M-103.47M-90.12M-72.41M-57.85M-48.43M-2.95M-1.63M-12.38M-11.34M-10.59M-10.23M-9.45M-11.74M-10.46M-7.86M-6.64M-5.2M-2.9M-1.7M600K
Treasury Stock0000000000000000000000000000000
Accumulated OCI00000000-2.86M-2.29M-1.8M-1.94M-1.74M-1.58M-1.5M-1.32M-6.2K-3.02K-7010000-4.85M-5.43M04.84K-6M-5.3M-4.2M-3.5M
Minority Interest0000000000000000000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Regulatory BLA transition uncertainty

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Base Strengthening Through Dilution

According to recent balance sheet data, AXGN's total assets expanded to $289.5M in 2026Q1 from $203.7M in 2024Q4, a trend that appears driven by equity-based capital raises rather than organic accumulation of retained earnings, which remain deeply negative at -$326.5M.

The trajectory of the balance sheet suggests a company prioritizing growth and infrastructure investment over immediate balance sheet self-sufficiency. While the asset base is growing, the persistent negative retained earnings indicate that the business model has yet to reach a point of sustainable internal capital generation.

Leverage Reduction Improves Financial Flexibility

As reported in financial statements, AXGN significantly reduced its total debt from $69.3M in 2023Q4 to $20.6M by 2026Q1, effectively lowering the debt-to-equity ratio from 0.72 to 0.08 over the same period, which suggests a strategic shift toward a cleaner capital structure.

This deleveraging appears to be a deliberate effort to reduce interest expense and financial risk as the company approaches critical regulatory milestones. Investors should monitor whether this lower leverage profile is maintained as the company continues to fund its BLA-related operational requirements.

Enhanced Liquidity Buffer Supports Operations

Based on the most recent quarterly figures, AXGN's cash position surged to $82.7M in 2026Q1, resulting in a current ratio of 7.10, which indicates a substantial improvement in short-term liquidity compared to the 2.89 ratio observed in 2023Q4.

The significant increase in cash and liquidity suggests the company has successfully fortified its balance sheet to withstand potential delays in the BLA approval process. This liquidity buffer appears sufficient to support ongoing clinical and commercial activities without immediate reliance on external debt financing.

Asset Composition Reflects Infrastructure Investment

Data from recent filings shows that net PPE remains a significant component of the asset base at $97.3M in 2026Q1, reflecting the company's heavy investment in the Alachua, Florida processing facility as a core pillar of its long-term manufacturing strategy.

The concentration of assets in specialized manufacturing infrastructure underscores the company's commitment to controlling its supply chain for human allografts. However, this asset-heavy profile warrants monitoring for potential impairment risks should the BLA transition or product demand fail to meet long-term expectations.

AXGN — Frequently Asked Questions

Quick answers to the most common questions about buying AXGN stock.

What are the total assets of AxoGen, Inc. (AXGN)?

As of 2025, AxoGen, Inc. (AXGN) had total assets of $221.7M including $120.4M in current assets.

How much debt does AxoGen, Inc. (AXGN) have?

AxoGen, Inc. (AXGN) carries total debt of $19.2M, offset by $35.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of AxoGen, Inc.?

AxoGen, Inc. (AXGN) has total shareholders' equity (book value) of $128.8M ($2.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is AxoGen, Inc.'s current ratio and liquidity?

AxoGen, Inc. (AXGN) reported a current ratio of 5.11x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.